[
  {
    "ts": null,
    "headline": "Johnson & Johnson stock underperforms Monday when compared to competitors despite daily gains",
    "summary": "Johnson & Johnson stock underperforms Monday when compared to competitors despite daily gains",
    "url": "https://finnhub.io/api/news?id=045d89bb51aaf897042168416b7c1c8289acd3f2ab5b6fdbb4d1dab5c372884f",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732552260,
      "headline": "Johnson & Johnson stock underperforms Monday when compared to competitors despite daily gains",
      "id": 131636556,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Johnson & Johnson stock underperforms Monday when compared to competitors despite daily gains",
      "url": "https://finnhub.io/api/news?id=045d89bb51aaf897042168416b7c1c8289acd3f2ab5b6fdbb4d1dab5c372884f"
    }
  },
  {
    "ts": null,
    "headline": "J&J Seeks FDA Nod for Subcutaneous Tremfya as Induction Regimen in UC",
    "summary": "If approved, JNJ's Tremfya will be the first IL-23 inhibitor to offer a choice of subcutaneous or intravenous use as induction treatment in ulcerative colitis.",
    "url": "https://finnhub.io/api/news?id=7b835e11e3dd59cbaccc5fe94a089290e93502e964fb7592f02d8ec37e7b5446",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732543680,
      "headline": "J&J Seeks FDA Nod for Subcutaneous Tremfya as Induction Regimen in UC",
      "id": 131630849,
      "image": "https://media.zenfs.com/en/zacks.com/f3f15a36f635cd8200884e1a968d4c3d",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "If approved, JNJ's Tremfya will be the first IL-23 inhibitor to offer a choice of subcutaneous or intravenous use as induction treatment in ulcerative colitis.",
      "url": "https://finnhub.io/api/news?id=7b835e11e3dd59cbaccc5fe94a089290e93502e964fb7592f02d8ec37e7b5446"
    }
  }
]